Abstract
<b/> Excitement and drug-development efforts aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway have declined due to the limited clinical performance of these inhibitors as monotherapies. New, more isoform-selective treatments, such as taselisib, promise to both expand the therapeutic window and increase efficacy. Cancer Discov; 7(7); 666-9. ©2017 AACR.See related article by Juric et al., p. 704.
©2017 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Humans
-
Imidazoles / therapeutic use*
-
Molecular Targeted Therapy*
-
Neoplasms / drug therapy*
-
Neoplasms / epidemiology
-
Neoplasms / genetics
-
Oxazepines / therapeutic use*
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Isoforms / antagonists & inhibitors
-
Proto-Oncogene Proteins c-akt / antagonists & inhibitors
-
Signal Transduction / drug effects*
-
TOR Serine-Threonine Kinases
Substances
-
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
-
Antineoplastic Agents
-
Imidazoles
-
Oxazepines
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Isoforms
-
MTOR protein, human
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases